The various PPPs at Servier as of January 2025

As of January 2025, Servier is involved in more than thirty public-private partnerships (PPPs) covering all therapeutic areas of interest to the Group and all stages of drug development.

Servier participates in six PPPs focused on drug research and discovery (identification and selection of therapeutic targets of interest, in vitro test configuration, and drug design):
à 4 cross-disciplinary projects (EUbOPEN, Blue Tools, ID Pro, and OASIS)
à 1 neurology project (EFFeCT)
à 1 oncology project (DMC)

Servier is involved in fourteen PPPs in translational medicine, particularly in the understanding of diseases and their progression, in vivo trial setup, and the use of translational tools:
à 5 cross-disciplinary projects (BIG PICTURE, CAPKR, LHASA, ImSAVAR, NECESSITY)
à 6 neurology projects (PPMI, ESMI, CPTA, NAF-DDC, INNOV4-ePIK, COMBINED BRAIN)
à 3 oncology projects (MPAACT, IMMUCAN, THEMA)

Servier participates in five PPPs in CMC (Chemistry, Manufacturing, and Controls) for the optimization and industrialization of scientific projects:
à 4 cross-disciplinary projects (CAMPUS BIOTECH DIGITAL, COLIBRI, TiO2, ChimSEP)
à 1 oncology project (T²EVOLVE)

Servier is engaged in five PPPs dedicated to sustainability and patient engagement:
à 5 cross-disciplinary projects (CARE, GreenChemForCE, PREMIER, PHARMECO, FACILITATE)

Finally, Servier is taking part in one PPP related to the post-marketing authorization phase:
à 1 cross-disciplinary project (BEAMER)